Synthetic lethality provides a framework for targeting the loss of function of tumor suppressor and DNA repair genes, as exemplified by the success of PARP inhibitors in the treatment of BRCA1/2-deficient tumors48,49. The gene discussed is BRCA1; the disease is neoplasm.